Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Med Sci Monit ; 23: 3746-3751, 2017 Aug 02.
Article in English | MEDLINE | ID: mdl-28765519

ABSTRACT

BACKGROUND The aim of the current study was to evaluate the anti-osteoarthritic and anti-inflammatory effect of naringin in a monosodium iodoacetate (MIA)- induced osteoarthritis (OA) model in rats. The anti-osteoarthritic potential of naringin was evaluated against the MIA-induced OA rat model. MATERIAL AND METHODS Wistar rats were used for the study and were divided into the following groups: normal control (saline-treated); group II (MIA-treated): group III (MIA+Naringin), and group IV (MIA+Indomethacin). The potential effect of naringin was evaluated via its effect on the level of proinflammatory cytokines, measuring the weight-bearing distribution, and histopathological analysis. RESULTS The anti-inflammatory effect of naringin was assessed in vitro in lipopolysaccharide-induced RAW 264.6 cells. The results suggest that naringin exerts an anti-inflammatory effect via reducing the production of the prostaglandin E2 (PGE2), nitric oxide (NO), interlukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in LPS-induced RAW cells. Additionally, naringin also supported the recovery of hind-limb weight-bearing, reduced the generation or production of inflammatory mediator and proinflammatory cytokines, and protected the tissue from the damage in the OA model. CONCLUSIONS Naringin appears to be an effective therapeutic drug for the treatment of the OA and OA-related symptoms.


Subject(s)
Flavanones/therapeutic use , Osteoarthritis/chemically induced , Osteoarthritis/drug therapy , Pain/drug therapy , Animals , Cytokines/blood , Cytokines/metabolism , Dinoprostone/blood , Dinoprostone/metabolism , Flavanones/pharmacology , Inflammation/blood , Inflammation/complications , Inflammation/drug therapy , Inflammation/pathology , Inflammation Mediators/metabolism , Iodoacetates , Lipopolysaccharides , Male , Mice , Nitric Oxide/metabolism , Osteoarthritis/blood , Osteoarthritis/complications , Pain/blood , Pain/complications , Pain/pathology , RAW 264.7 Cells , Rats, Sprague-Dawley , Rats, Wistar , Weight-Bearing
2.
Ren Fail ; 39(1): 561-565, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28726586

ABSTRACT

Here, we reported our clinical application of ureterorenoscope (URS) and flexible URS lithotripsy in stone removal on 10 cases of excised living donor kidney graft. After the extraction of donor kidney by retroperitoneal laparoscopy, the donor graft was perfused with 4 °C HCA solution. Calculus between 2-4 mm were removed intact with lithotomy forceps under direct vision of URS. Larger calculi of >4 mm were fractured with flexible URS combining holmium laser lithotripsy. Fragments of the calculus were extracted with basket extractor and lithotomy forceps. All operations were successful. The operation time was 14-31 min (average 21.2 ± 6.3 min). The kidneys were then transplanted to the recipients using routine procedure. The transplanted kidneys functioned well after transplantation. Gross hematuria resolved 1-4 d after operation (average 2.6 ± 0.9 d). The transplanted kidneys functioned well without early complications such as functional recovery delay and acute graft rejection. The donors and recipients were followed for 12 months. The size of the transplanted kidneys was normal and new stones or urinary obstruction was not seen upon urinary color Doppler ultrasound examination. In conclusion, we believe it is feasible, safe and effective to use URS or flexible URS combining holmium laser lithotripsy on extracorporeal living donor kidney.


Subject(s)
Allografts/surgery , Kidney Calculi/surgery , Kidney/surgery , Lasers, Solid-State/therapeutic use , Lithotripsy, Laser/methods , Adult , Allografts/pathology , Feasibility Studies , Female , Humans , Kidney/pathology , Kidney Calculi/diagnostic imaging , Kidney Transplantation/methods , Laparoscopy , Lithotripsy, Laser/instrumentation , Living Donors , Male , Middle Aged , Tissue and Organ Harvesting/methods , Tomography, X-Ray Computed , Ureteroscopes
3.
Ren Fail ; 37(5): 840-4, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25707525

ABSTRACT

This study investigated the feasibility of percutaneous nephrolithotomy (PCNL) combined with retroperitoneal laparoendoscopic single-site partial nephrectomy (LESS-PN) in one-stage treatment of homolateral renal calculi and tumors. Between October 2010 and July 2014 one-stage PCNL combined LESS-PN surgery was performed in 23 patients with homolateral renal calculi and tumors. Patients included 17 male and 8 female, ranged from 31 to 66 years old with a median age of 42.7. Operative parameters and occurrence rate of complications were recorded. In all cases renal tumors were successfully removed without converting to open surgery. One-stage clearance rate for renal calculi was 21/23 (91.3%), leaving two cases for second-stage operation of flexible ureteroscope lithotomy. The operation time was 95-186 min; average 128 min. Intraoperative blood loss was 40-200 mL; average 130 mL. Median warm ischemia time was 23.8 ± 9.5 min. There were no serious post-operative complications such as massive hemorrhage or urine leakage. Length of stay was 5-7 days, average 6 days. There was no recurrence of renal calculus, renal tumors or ureterostenosis and kidney functions were normal. In conclusion, with good practice, one-stage combined operation of PCNL and retroperitoneal LESS-PN in removing homolateral renal tumors and calculi was safe, feasible and would potentially reduce the operative trauma.


Subject(s)
Kidney Calculi/surgery , Kidney Neoplasms/surgery , Laparoscopy/methods , Nephrectomy/methods , Nephrostomy, Percutaneous/methods , Adult , Aged , Female , Humans , Male , Middle Aged , Operative Time , Tomography, X-Ray Computed , Treatment Outcome , Ultrasonography, Doppler , Warm Ischemia
SELECTION OF CITATIONS
SEARCH DETAIL
...